Consensus Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-01-16 EST			5-day change	1st Jan Change
81.99 ^USD	-3.26%		+2.21%	-6.13%

01-13	Protagonist Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 08:15 AM
01-05	Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera	CI

Evolution of the Average Target: Protagonist Therapeutics, Inc.

Evolution of the Target Price: Protagonist Therapeutics, Inc.

Changes in Analyst Recommendations: Protagonist Therapeutics, Inc.

862.AnAbzdB95_fSPyKBBZuLcry19xj160DYaYlS1flhwcI.Ui9-lbYNpaO6VUH3Sej_I_H0nCiTmhqtUMcgp5oGq_ZpM12Vlk-psblOFg~0a0d2a099f4f66833f213d8189a25479

Analysts' recommendations: Protagonist Therapeutics, Inc.

01-05	Truist Adjusts Price Target on Protagonist Therapeutics to $110 From $88, Maintains Buy Rating	MT
25-10-28	Wedbush Raises Price Target on Protagonist Therapeutics to $86 From $70, Keeps Outperform Rating	MT
25-10-28	Truist Raises Price Target on Protagonist Therapeutics to $88 From $76, Keeps Buy Rating	MT
25-10-27	Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial	MT
25-10-10	Johnson & Johnson in Talks to Acquire Protagonist Therapeutics, WSJ Reports	MT
25-10-08	Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says	MT
25-09-17	J&J's experimental psoriasis drug shows promise against Bristol's treatment	RE
25-09-17	Barclays Initiates Protagonist Therapeutics at Overweight	MT
25-09-12	Leerink Partners Initiates Protagonist Therapeutics at Outperform With $73 Price Target	MT
25-06-17	Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target	MT
25-03-11	Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating	MT
25-03-10	Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating	MT
24-12-06	Goldman Sachs Initiates Protagonist Therapeutics at Neutral With $47 Price Target	MT
24-11-05	Wedbush Initiates Protagonist Therapeutics at Outperform With $58 Price Target	MT
24-09-24	TD Cowen Initiates Protagonist Therapeutics at Buy	MT
24-09-09	Truist Initiates Protagonist Therapeutics at Buy With $60 Price Target	MT
24-07-25	JPMorgan Adjusts Price Target on Protagonist Therapeutics to $48 From $39, Maintains Overweight Rating	MT
24-07-24	BTIG Raises Price Target on Protagonist Therapeutics to $51 From $41, Maintains Buy Rating	MT
24-06-11	Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing	MT
24-06-11	Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing	MT
24-04-03	Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	MT
24-02-28	JPMorgan Adjusts Price Target on Protagonist Therapeutics to $37 From $34, Maintains Overweight Rating	MT
23-10-30	Capital One Starts Protagonist Therapeutics With Overweight Rating, $32 Price Target	MT
23-09-25	JPMorgan Lowers Protagonist Therapeutics' Price Target to $34 From $36, Keeps Overweight Rating	MT
23-07-06	JMP Securities Raises Protagonist Therapeutics' Price Target to $35 From $28, Keeps Market Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PROTAGONIST THERAPEUTICS, INC.					+17.49%
	LONZA GROUP AG					+21.2%
	IQVIA HOLDINGS INC.					+9.24%
	BEONE MEDICINES AG					+19.52%
	CELLTRION, INC.					+12.8%
	REVOLUTION MEDICINES, INC.					-24.34%
	MEDPACE HOLDINGS, INC.					-10.66%
	Average					+6.46%
	Weighted average by Cap.					+9.24%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

81.99USD

Average target price

96.33USD

Spread / Average Target

+17.49%

High Price Target

115.00USD

Spread / Highest target

+40.26%

Low Price Target

65.00USD

Spread / Lowest Target

-20.72%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Truist Securities
Wedbush
Barclays
Leerink Partners
Citigroup
Goldman Sachs
TD Cowen
JPMorgan Chase
Capital One Securities
JMP Securities
HC Wainwright
Piper Sandler
SVB Leerink
BTIG
Northland Securities